Context Therapeutics up on uterus cancer drug trial data

Context Therapeutics

06/02/2023 13:41

** Shares of Context Therapeutics Inc  CNTX.O  rise 9.7% to
$1 premarket
    ** Drug developer reports positive data from its
experimental drug, ONA-XR's, mid-stage stage endometrial cancer
(EC) treatment trial 
    ** The trial is testing ONA-XR in treating hormone-driven
EC, an aggressive cancer of the uterus, in combination with
breast cancer treatment medicine, anastrozole
    ** ONA-XR's initial data signals positive clinical activity
and confirmed tumor shrinkage and continues to be safe and
well-tolerated - Co
    ** Updated data on the trial is expected to be provided in
Q2 of 2023
    ** CNTX shares fell 75.5% last year
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))